Jan 2, 2025 · Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that the US Food and Drug Administration (FDA) has approved Journavx (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.

Dec 30, 2024 · The life sciences industry experienced volatility in 2024, marked by pipeline growth, biologics breakthroughs, and evolving GLP-1 therapies. Challenges in trials, manufacturing, and commercialization persisted, driving adoption of AI and innovative pricing models as the sector prepares for further innovation in 2025.

Jan 10, 2025 · The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering interchangeable options. Over 74% of approvals occurred on the first review cycle, reinforcing the FDA's efficiency. The EMA also advanced, recommending 114 new medicines, including biosimilars and rare disease therapies.

Sep 22, 2024 · In the 2024 US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have criticized high drug prices, raising uncertainty for the industry. While Trump targeted generics, biosimilars, and international price comparisons during his term, Harris has been associated with pricing transparency and the Inflation Reduction Act (IRA), which ...

Sep 12, 2024 · PanTera was founded in 2022 with the primary goal of enabling large-scale production of actinium225 (225Ac), which is crucial to enable a new class of targeted cancer treatments known as Targeted Alpha Therapy.

Jan 30, 2025 · The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio.

Jan 14, 2025 · US genetic medicines company Scribe Therpeutics, which is seeking to unlock the potential of CRISPR to transform human health, announced the achievement of a success milestone for one of the targets in its research collaboration with French pharma major Sanofi (Euronext: SAN) to develop in vivo CRISPR-based therapeutics.

Atopia's lead compound, ATP-R13, is designed as an oral first-line preventive and therapeutic treatment against asthma, eczema, food allergies, and related type-II atopic diseases.

Jan 27, 2025 · Japan’s Mitsubishi Chemical Group has resolved, at a meeting of the board of directors held today, to transfer its consolidated subsidiary, Mitsubishi Tanabe Pharma (MTPC), which engages in the manufacturing and sales of pharmaceutical products, to K.K. BCJ-94, a special purpose company indirectly owned by Bain Capital for …

Jan 17, 2025 · The US Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), has announced the selection of 15 new drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act (IRA), the negotiations with ...